Group items tagged

A proprietary extract prepared from co-cultured mycelia of several species of Basidiomycete mushrooms, including shiitake (Lentinus edodes), active hexose correlated compound (AHCC) is extracted from mushrooms using hot water following an enzyme pretreatment, but specific mushroom source and preparation details have not been fully disclosed. Patients use this to prevent and treat cancer. Animal studies suggest that AHCC has antioxidant effects and may protect against disorders induced by oxidative stress (1) and may also enhance resistance against bacterial (2) (7)and viral infections (3). In healthy humans, AHCC increased dendritic cell number and function (4) In vitro and animal studies show that AHCC exhibits some anticancer activities, but the results of these studies are vague

Active Hexose Correlated Compound (AHCC) is an alpha-glucan rich nutritional supplement produced from the mycelia of shiitake (Lentinula edodes) of the basidiomycete family of mushrooms, and should not be confused or used as a drug or medicine.[1][2] AHCC was originally designed to lower high-blood pressure. However, researchers at Tokyo University found AHCC's influence upon the innate immune system highly beneficial and published the results in 1992, though not in the commonly indexed scientific literature. In this study, researchers found that AHCC significantly increased natural killer (NK) cell activity in cancer patients, and also enhanced the effects of killer T-cells, and cytokines (interferon, IL-12, TNF-alpha

A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells. The study was conducted in a double-blind randomized fashion where twenty-one healthy subjects received a placebo or AHCC at 3.0 g/day for 4 weeks. Blood samples were obtained and measured at baseline and at 4 weeks. The number of circulating types of DCs was measured which included CD 11c+ DCs (myeloid DC population; DC1) and CD11c- DCs (lymphoid DC population; DC2). Other parameters measured included mixed-leukocyte reaction (MLR), natural killer (NK) cell activity, the proliferative response of T lymphocytes toward mitogen (phytohemagglutinin [PHA]) and cytokine production of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, and (alpha)-tumor necrosis factor.

A recently completed study from researchers at Colorado State University supported by the Division of Vector-Borne Infectious Diseases with the Centers for Disease Control and Prevention (CDC) has demonstrated that AHCC(R) (Active Hexose Correlated Compound) enhances host resistance by boosting protective immune responses specific to the West Nile Virus. Since its discovery in the United States in 1999, infections caused by the West Nile Virus have become a major public health concern. West Nile Virus is caused by people being bitten by mosquitoes infected with the virus. According to the CDC, there have been 28,018 reported cases with 1,092 deaths since 1999. In 2003, the highest number of cases was reported at nearly 10,000. Currently there is no effective treatment for the disease.

Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. Wang S, Welte T, Fang H, Chang GJ, Born WK, O'Brien RL, Sun B, Fujii H, Kosuna K, Wang T. J Nutr. 2009 Mar;139(3):598-602. Epub 2009 Jan 13. PMID: 19141700 doi:10.3945/jn.108.100297